Browse Categories
UroToday
| ASCO 2009 - A Multicenter Phase II Study of Cisplatin, Gemcitabine, and Bevacizumab as First-Line Chemotherapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU-0475 - Session Highlights |
 |
 |
Wed, 03 June 2009
Last Updated ( Wed, 03 June 2009 )
Login to read more...| ASCO 2009 - Randomized Trial of p53 Targeted Adjuvant Therapy for Patients with Organ-Confined Node-Negative Urothelial Bladder Cancer - Session Highlights |
|
|
Wed, 03 June 2009
Last Updated ( Wed, 03 June 2009 )
Login to read more...| ASCO 2009 - Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity - Session Highlights |
|
|
Wed, 03 June 2009
| ASCO 2009 - VEGF Single Nucleotide Polymorphisms and Correlation to Sunitinib-Induced Hypertension in Metastatic Renal Cell Carcinoma Patients - Session Highlights |
|
|
Wed, 03 June 2009
| ASCO 2009 - Phase II Presurgical Study of Bevacizumab Plus Erlotinib in Untreated Patients with Metastatic Renal Cell Carcinoma - Session Highlights |
|
|
Wed, 03 June 2009
| ASCO 2009 - Use of CA9 Gene Single Nucleotide Polymorphisms to Predict Prognosis and Treatment Response of Metastatic Renal Cell Carcinoma - Session Highlights |
|
|
Wed, 03 June 2009
Last Updated ( Wed, 03 June 2009 )
Login to read more...| ASCO 2009 - Final Results of the Phase III, Randomized, Double-Blind AVOREN Trial of First-Line Bevacizumab + Interferon-α2a in Metastatic Renal Cell Carcinoma - Session Highlights |
|
|
Wed, 03 June 2009
| ASCO 2009 - A Randomized, Double-Blind Phase III Study of Pazopanib in Treatment-Naive and Cytokine-Pretreated Patients with Advanced Renal Cell Carcinoma - Session Highlights |
|
|
Wed, 03 June 2009
Last Updated ( Wed, 03 June 2009 )
Login to read more...